| Title： | Expert consensus on rational use of osteoporosis drugs (2023) |
| Edition： | Original |
| Classification： | Experts consensus |
| Field： | Treatment |
| Countries and regions： | China |
| Guidelines users： | Health care workers |
| Evidence classification method： | Oxford Centre for Evidence-Based Medicine: Levels of Evidence |
| Development unit： | Hospital Pharmacy Professional Committee of Chinese Pharmaceutical Association |
| Registration time: | 2023-09-07 |
| Registration number： | PREPARE-2023CN679 |
| Purpose of the guideline: | To offer evidence-based and practical recommendations for the rational utilization of osteoporosis medications in clinical settings, with a focus on ensuring patient safety and optimizing treatment outcomes. |
